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Abstract
Background: The optimal operative approach for carcinoma at the lower esophagus and
esophagogastric junction remains controversial. The aim of this study was to assess a single unit
experience of transhiatal esophagectomy in an era when the use of systemic oncological therapies
has increased dramatically.
Study Design: Between January 2000 and November 2006, 215 consecutive patients (182 males,
33 females, median age = 65 years) underwent transhiatal esophagectomy; invasive malignancy was
detected preoperatively in 188 patients. 90 patients (42%) received neoadjuvant chemotherapy.
Prospective data was obtained for these patients and cross-referenced with cancer registry survival
data.
Results: There were 2 in-hospital deaths (0.9%). Major complications included: respiratory
complications in 65 patients (30%), cardiovascular complications in 31 patients (14%) and clinically
apparent anastomotic leak in 12 patients (6%). Median length of hospital stay was 14 days. The
radicality of resection was inversely related to T stage: an R0 resection was achieved in 98–100%
of T0/1 tumors and only 14% of T4 tumors. With a median follow up of 26 months, one and five
year survival rates were estimated at 81% and 48% respectively.
Conclusion: Transhiatal esophagectomy is an effective operative approach for tumors of the
infracarinal esophagus and the esophagogastric junction. It is associated with low mortality and
morbidity and a five survival rate of nearly 50% when combined with neoadjuvant chemotherapy.
Introduction
During the last thirty years, there has been a marked
increase in the incidence of adenocarcinoma close to the
esophagogastric junction whilst the incidence of squa-
mous cell carcinoma of the esophagus has remained rela-
tively unchanged [1]. Surgical resection of tumors in the
esophagus and esophagogastric junction has been based
upon the concept that, if all neoplastic tissue can be
removed, a worthwhile period of survival and possibly
cure can be achieved. Despite oncological advances, surgi-
cal resection is the only treatment that has repeatedly been
shown to prolong survival, albeit in only 30% of patients
[2].
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ferred surgical approach in patients with benign disease or
early tumors or those patients with more advanced dis-
ease who would not tolerate a thoracotomy. This
approach has been criticized because of the lack of a for-
mal two field lymphadenectomy and the failure to com-
pletely resect the tumor under direct vision [2].
Transhiatal esophagectomy has been the favoured opera-
tive approach in our institution for managing both carci-
noma of the oesophagus below the level of the carina and
type I and II tumours of the esophagogastric junction. It
has also been utilised for benign lower oesophageal dis-
ease including high grade dysplasia. This study evaluates
our experience and outcomes with transhiatal esophagec-
tomy in an era in which the use of neoadjuvant chemo-
therapy became more prevalent.
Methods
Study population
Between January 2000 and January 2007, 215 patients
with benign or malignant disease of the intrathoracic
esophagus and type I and II tumours of the esophagogas-
tric junction underwent transhiatal esophagectomy at our
institution. Prospective data on these 215 consecutive
patients was collected from consultant databases supple-
mented by cancer registry data and case note review. A fur-
ther 152 patients underwent transthoracic
esophagectomy during the same time period and were
excluded from analysis. Ethical committee approval was
obtained for this study and the need for individual patient
consent was waived.
Preoperative evaluation and treatment
Routine preoperative evaluation involved upper gastroin-
testinal endoscopy with biopsy, endoscopic ultrasound
and computed tomography of the neck, chest and abdo-
men. Staging laparoscopy and PET scanning were per-
formed on a selective basis. Operative risk analysis
included standard blood examination, electrocardiogra-
phy, echocardiography, pulmonary function tests and car-
diopulmonary exercise tests (in higher risk patients).
Surgery was offered to medically fit patients following dis-
cussion at a multidisciplinary meeting.
90 patients in the study group (42%) received preopera-
tive chemotherapy based upon the presence of T3 disease
or positive lymph nodes on preoperative staging. The pre-
ferred chemotherapy at our institution consisted of three
cycles of combination epirubicin, cisplatin and 5-fluorou-
racil each given over three weeks, following the MAGIC
trial protocol [3].
Operative technique
All patients underwent subtotal esophagectomy and prox-
imal gastrectomy by the transhiatal technique as
described in detail by Orringer. [4-6] An initial laparot-
omy was performed through a rooftop incision to confirm
tumour resectability. After abdominal exploration and
gastric mobilisation had been performed, the esophageal
hiatus was enlarged by splitting the diaphragm anteriorly
and retractors were positioned to facilitate exposure of the
intrathoracic esophagus up to the level of the carina. This
enabled en bloc resection of the esophagus and
paraesophageal tissue including the crura and pleura (if
indicated) under direct visualisation. Standard lymph
node dissection involved lymph nodes in the lower medi-
astinum, around the esophagogastric junction and along
the lesser curvature of the stomach. A radical lymph node
dissection was performed at the origins of the left gastric
and common hepatic arteries; lymph nodes at the celiac
axis were included when enlarged and resectable. A less
radical resection was performed for patients with benign
disease. Gastrointestinal continuity was re-established
with a narrow gastric tube vascularized by the right gastro-
epiploic artery in all cases, positioned within the posterior
mediastinum. An end to side hand sewn single layer
esophagogastric anastomosis was fashioned in the neck
through a left sided cervical incision. Transmediastinal
chest drains and placement of a feeding jejunostomy were
performed in all patients.
Pathological examination
Pathology specimens were processed by three dedicated
esophagogastric pathologists according to Royal College
of Pathologists' guidelines. [7] Tumors of the esoph-
agogastric junction were categorized according to Siew-
ert's classification based upon macroscopic tumor
location, irrespective of the presence of Barrett mucosa.
[8] Type I adenocarcinoma of the esophagogastric junc-
tion was staged according to esophageal pTNM classifica-
tion whilst type II adenocarcinoma of the esophagogastric
junction were staged according to gastric pTNM classifica-
tion. [9] To ensure standardized histopathology results,
all early specimens were re-categorized according to the
latest guidelines.
Follow up
During the immediate postoperative period, patients were
kept intubated and ventilated until the following morn-
ing. Following extubation, patients were monitored on a
surgical High Dependency Unit until well enough to be
managed on a surgical ward. Oral nutrition was recom-
menced if a water soluble contrast swallow examination
failed to demonstrate an anastomotic leak on the seventh
day.
After discharge, patients were routinely followed up at 3–
6 monthly intervals. Patients were offered either adjuvant
chemotherapy (up to a maximum of 6 cycles) or chemo-
radiotherapy (if any margins were positive) based uponPage 2 of 9
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cally determined response to any preoperative treatment.
Additional diagnostic procedures were only performed if
indicated by the development of any new symptoms sug-
gestive of recurrent disease. In the presence of recurrent
disease, further oncological or palliative options were
considered. The median duration of postoperative follow
up was 26 months (range = 1–82 months) for all patients
and 36 months (range = 2–82 months) for those alive at
final follow up.
Statistics
Overall survival was defined as the time interval from the
date of operation until the date of death or most recent
follow up. Disease free survival was defined as the time
interval from the date of operation until the date of dis-
ease recurrence or most recent follow up. Survival curves
were calculated according to the Kaplan-Meier method.
Univariate group comparisons were calculated using the
log rank test. Categorical variables were assessed using
Fisher's exact test and continuous variables were assessed
by student's t test [10]. A p value < 0.05 was regarded as
statistically significant. Statistical analysis was performed
with Graphpad Prism v3.0 and Instat v2.0 (GraphPad
Software, San Diego California USA).
Results
Preoperative features
The demographic details of the 215 patients undergoing
transhiatal esophagectomy are shown in Table 1. Dys-
phagia and weight loss were present in 73% and 48% of
patients respectively with preoperatively confirmed malig-
nant tumours. Twenty two patients (10%) had an asymp-
tomatic cancer or high grade dysplasia detected during
endoscopic surveillance of Barrretts oesophagus. Three
patients (1%) underwent urgent transhiatal esophagec-
tomy following endoscopic tumor perforation. According
to the American Society of Anesthesiologists (ASA) classi-
fication [11], operative risk was scored as ASA-I (n = 15),
ASA-II (n = 125), ASA-III (n = 72) or ASA-IV (n = 3).
Intraoperative surgical findings
Only one patient required intraoperative conversion to a
right posterolateral thoracotomy due to tumor adherence
at the carina and difficulties in achieving macroscopic
tumor clearance through the esophageal hiatus. Macro-
scopic tumor clearance could not be achieved in one
patient due to the presence of extensive left gastric and
celiac axis lymphadenopathy. The median operative time
was 151 minutes (range = 93–276 minutes).
Postoperative course
There were two in-hospital deaths during this study
(<1%). One patient, a 74 year old man, with a past medi-
cal history including pneumonectomy for lung cancer and
a previous myocardial infarction, developed respiratory
failure requiring prolonged ITU admission and respira-
tory support; he died from myocardial infarction on day
44. The second patient, a 70 year old man, died from a
pulmonary embolus on day 13 in ITU following admis-
sion with multiorgan failure secondary to chest sepsis.
Major postoperative complications are listed in Table 2.
All 12 patients with clinically apparent anastomotic leaks
were managed conservatively with opening the cervical
wound to allow adequate wound drainage and reduction
of oral intake combimed with jejunostomy tube feeding.
None of these patients required re-operation for their
Table 1: Demographic data on 215 patients undergoing transhiatal esophagectomy.
Demographics n
Sex (M:F) 182:33
Age (range) 65 years (29–83 years)
Preoperative indication
Adenocarcinoma 162 (75%)
Squamous cell carcinoma 23 (11%)
Other malignant tumours 3 (1%)
Benign tumours 1 (0.5%)
High grade dysplasia 23 (11%)
Benign strictures 3 (1%)
Preoperative staging (in 188 patients with preoperatively confirmed malignant tumours)
T1 28 (15%)
T2 48 (26%)
T3 108 (57%)
T4 4 (2%)
N0 113 (60%)
N+ 75 (40%)Page 3 of 9
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in the early post-operative stage for: bleeding (n = 4),
bowel obstruction (n = 3), chyle leak (n = 2) and wound
dehiscence (n = 1). Unplanned ITU admission was
required in 29 patients (14%), most commonly for respi-
ratory failure. The median ITU stay in this group was 7
days (range 2–44 days). Overall median length of hospital
stay was 14 days (range 8–95 days). All patients were dis-
charged directly home and the in-patient stay reflects the
need for sufficient mobility and tolerance of an adequate
oral diet prior to discharge.
Oncological outcomes
Histopathological analysis of the operative specimens in
the 215 patients revealed the following tumor types: ade-
nocarcinoma (n = 169), squamous cell carcinoma (n =
22), high grade dysplasia (n = 17), adenosquamous carci-
noma (n = 3), benign strictures only (n = 3) and spindle
cell tumor (n = 1). In 3 patients, all initially diagnosed
with adenocarcinoma, there was a complete pathological
response to neoadjuvant chemotherapy whilst, in a fur-
ther 2 patients, there was residual adenocarcinoma in
lymph nodes only. The type of esophagogastric junctional
tumour in 169 patients with adenocarcinoma was classi-
fied as follows: type I (n = 93), type II (n = 70) or type III
(n = 6). All 6 patients with type 3 tumors had been preop-
eratively staged as type 2 tumours.
Macroscopic tumour clearance was achieved in 193 out of
194 patients with pathological evidence of invasive malig-
nancy. Residual microscopic disease was found at the
proximal or distal resection margins in 11 patients (5%),
all in association with positive circumferential resection
margins and involved lymph nodes. Eighty eight patients
(46%) were subsequently found to have tumor cells at or
within 1 mm of the esophageal adventitia or the gastric
serosal surface.
The radicality of resection in relation to tumour infiltra-
tion and involved lymph nodes is shown in Table 3. The
median lymph node yield in all patients was 12 (range 1–
52). Both tumour stage and radicality of resection were
independent predictors of overall survival on univariate
analysis (Figures 1 &2).
Recurrence and survival
All patients undergoing transhiatal esophagectomy for
benign disease remain alive on follow up. Excluding the
two in-hospital deaths, 79 patients (40%) who underwent
esophagectomy for invasive malignancy have died on fol-
low up. The causes of death are as follows: locoregional
recurrence (n = 14), systemic metastases (n = 27), combi-
nation of locoregional recurrence and systemic metastases
(n = 29), medical causes (n = 5), ongoing surgical compli-
cations (n = 1) and cause unable to be identified (n = 3).
In total, 39% of patients developed recurrent disease dur-
ing the period of study. The median survival for all
patients undergoing transhiatal esophagectomy for inva-
sive malignancy was 43 months and the one year and five
year survival rates were estimated at 81% and 48% respec-
tively (Figure 3). There was no difference in overall or dis-
ease free survival between patients with type I and II
adenocarcinoma of the oesophagogastric junction.
Discussion
This study has demonstrated that transhiatal esophagec-
tomy can be associated with a low morbidity and a mor-
tality of less than 1%. Although other units have reported
similar results for transhiatal esophagectomy, several mul-
ticentre studies and national audits have shown that the
mortality for all types of esophagectomy may exceed 10%
[12-16]. It is recognised that high volume centres with a
concentration of surgical, critical care and interventional
radiological expertise achieve better outcomes. [17-19]
The rationale for a transhiatal esophagectomy is the
avoidance of a thoracotomy, thereby reducing the inci-
dence of pulmonary complications, and the fashioning of
a cervical anastomosis so that the clinical consequences of
any anastomotic leak are minimized [12,13]. Critics of the
transhiatal approach argue that there is a risk of blind
intrathoracic injuries such as massive bleeding from the
azygous vein, tracheal injury and episodes of cardiac
instability resulting from retraction and surgical manipu-
lation within the mediastinum. Case selection for transhi-
atal esophagectomy is crucial to prevent these problems
Table 2: Major postoperative complications
Complication n (%)
Clinical anastomotic leak 12 (5.6)
Respiratorya 65 (30)
Cardiovascular 31 (14)
Recurrent laryngeal nerve neuropraxia 6 (3)
Wound infection 22 (10)
Renal failure 6 (3)
Chyle leak 5 (2)
Deep vein thrombosis/pulmonary embolism 3 (1)
aRespiratory complications are defined as respiratory failure, lower 
respiratory tract infection and symptomatic pleural effusion requiring 
drainage.
Table 3: Pathology results from 194 patients undergoing 
transhiatal esophagectomy for invasive malignancy.
N0 N+ R0 R1 R2 % R0 resections
T0 3 2 5 100%
T1 35 7 41 1 98%
T2 23 38 41 20 68%
T3 25 52 19 57 1 25%
T4 1 5 1 6 17%Page 4 of 9
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for more proximally located esophageal tumors. It is the
authors' policy that only patients with subcarinal tumors
identified on preoperative imaging and confirmed by
transhiatal dissection to above the proximal macroscopic
extent of the tumor are suitable for the transhiatal
approach. In the current series, only one patient required
intraoperative conversion to a thoracotomy to obtain
tumor clearance and 2 patients (1%) required reoperation
for bleeding (both of these patients had active intratho-
racic bleeding although none were associated with an
azygous vein injury). Clinically apparent anastomotic
leaks occurred in 6% of patients and all were managed
successfully with conservative treatment. The data from
this study supports the concept that a transhiatal
esophagectomy in appropriately selected patients is safe
and feasible.
Surgeons who advocate a transthoracic approach argue
that neglecting to perform a mediastinal lymphadenec-
tomy risks leaving behind residual tumour, resulting in
higher rates of locoregional recurrence and worse overall
survival. [20-22] However, the additional value of formal
mediastinal lymph node dissection remains controversial
in Western patients, especially with the concept that
lymph node involvement may reflect systemic micromet-
astatic disease and that extended resections will not alter
the natural history of this disease. Reported differences in
recurrence and survival may merely represent a stage
migration effect due to an increased accuracy of histolog-
ical staging. [2,23,24] Portale et al recently suggested that
extended en bloc transthoracic resections were signifi-
cantly associated with better survival rates of up to 50%
compared to transhiatal resections and that this could not
be ascribed to a stage migration effect. [21] R0 status
(defined in this study as clear circumferential and longitu-
Survival curves comparing overall survival for p (and yp) T0–2 tumours versus p (and yp) T3–4 tumoursFigure 1
Survival curves comparing overall survival for p (and yp) T0–2 tumours versus p (and yp) T3–4 tumours.
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factor for survival. Advocates of a transthoracic esophagec-
tomy have suggested that the transhiatal approach limits
the ability to achieve an R0 resection [20-22]. Macro-
scopic tumour clearance was achieved in all but one
patient in the current study. Longitudinal margin involve-
ment, especially at the proximal margin, has been shown
to independently impact on survival via increased loco-
regional recurrence. The rate of positive longitudinal mar-
gins in this study was 5% which is in keeping with other
published series [25]. The problem of a positive gastric
resection margin at transhiatal esophagectomy has
recently been addressed by DiMusto and Orringer [26].
They achieved a negative gastric margin in 98% of over
1000 patients treated. In the few patients who had a posi-
tive gastric margin, they found that 80% die with distant
metastases, which would not be influenced by more
extensive gastric resection, and, in about 20%, local tumor
recurrence in the intrathoracic stomach was usually
asymptomatic. They also demonstrated that adjuvant
therapy for a positive gastric margin was usually unhelp-
ful. A similar picture was seen in the current study with all
five patients with involved distal resection margins devel-
oping systemic metastases.
The role of circumferential resection margin (CRM)
involvement is more controversial. Khan et al concluded
that a positive CRM did not influence outcome. [27], but
this has been disputed by other studies which suggested
that it may independently predict survival [28]. One of
these was performed by Maynard and colleagues who
recently studied 242 patients undergoing esophagectomy
and reported higher rates of local recurrence in patients
with a positive CRM. Interestingly, there was no difference
in CRM positivity when comparing different operative
approaches [29].
In our population, CRM involvement was encountered in
46% of patients with malignant disease, predominantly
affecting those with T3 tumours, and this was the main
Survival curves comparing overall survival for R0 and R1–2 resectionsFigure 2
Survival curves comparing overall survival for R0 and R1–2 resections. There was only one R2 resection.Page 6 of 9
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rates varied from 97–100% with T0/1 tumours to 0–17%
for T3–4 tumours. In keeping with previous studies, R0
resections were significantly associated with improved
overall survival and hence the group benefiting most from
this operative approach would appear to be those patients
with early (T1–2) tumours. [20-22]
Advocates of more radical en-bloc transthoracic strategies
argue that their approach may reduce rates of CRM
involvement although this is yet to be proven [28].
Regardless of the operative technique, it is often difficult
to obtain circumferential clearance due to the proximity
of vital structures and the lack of any fascial boundaries.
[13,28] The local recurrence rates in this study compare
favourably to previous studies of both transhiatal and
transthoracic esophagectomy [20,21,30,31]. Further-
more, the predominant pattern of recurrence was haema-
togenous metastatic disease (present in 70% of patients
with disease relapse), mirroring the patterns seen with
more radical en-bloc strategies [32]. These patterns of
early systemic relapse were also noted by Orringer in his
analysis of 2000 esophagectomy patients [33].
To date, there has been only one randomised controlled
trial comparing transthoracic and transhiatal approaches
and this failed to show any significant differences in radi-
cality of surgery or survival at the cost of increased postop-
erative morbidity in the transthoracic group. [34] Recent
five year survival data from this trial have again failed to
demonstrate a survival benefit for the transthoracic
approach although a sub-group of patients with oesopha-
geal cancer and 1–8 involved lymph nodes appear to have
improved disease-free survival. This study did not include
chemotherapy and overall five year survival rates were
34% (Transhiatal) and 36% (Transthoracic) with in-hop-
Kaplan Meier survival curves for overall survival of 21 patients with benign disease and 194 patients with invasive malignancy undergoing transh atal esophagectomyFigu e 3
Kaplan Meier survival curves for overall survival of 21 patients with benign disease and 194 patients with inva-
sive malignancy undergoing transhiatal esophagectomy.
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meta-analyses have attempted to compare the two
approaches and have favoured the transhiatal approach in
terms of early morbidity and mortality with no long term
survival disadvantage [22,36]. Despite this evidence, it
remains difficult preoperatively to select the appropriate
operative approach for individual patients.
Over the last few decades, the survival rates following
esophagectomy have significantly improved, largely as a
result of improvements in postoperative mortality. The
one year survival rate of 81% in the current study for
patients with invasive malignancy compares very favora-
bly with the Western standard from the 1990s of 61%.
[37] Furthermore, quality of life data suggests patients
undergoing a transhiatal approach have fewer physical
symptoms and better activity levels in the short term com-
pared to the transthoracic approach although these differ-
ences become less evident by 1 year. [38] Several authors
have emphasized the central role of surgery in achieving
five year survival rates of approximately 50%. [21,30] It is
increasingly recognized that there is an important role for
oncological treatments in the perioperative management
of esophageal and esophagogastric junctional cancer. The
survival advantages associated with chemotherapy in both
the MRC OEO2 and MRC MAGIC trials have significantly
influenced surgical decision making in the UK. [3,39,40]
The current series, which combined transhiatal
esophagectomy with neoadjuvant chemotherapy in 42%
of patients, has achieved equivalent five year survival
results to Portale et al but with a greater preponderance of
AJCC stage II and III disease. A complete pathological
response was seen in 4% of patients receiving neoadju-
vant chemotherapy and for many patients, there was little
or no histological evidence of response. This emphasizes
the need to identify potential responders prior to treat-
ment, and also for the development of new chemothera-
peutic agents. [21]
The development of high volume centres within the UK
and the increasing use of (neo)adjuvant therapies have
undoubtedly improved both the short term surgical
results as well as the long term oncological outcomes of
these patients. In summary, we have shown that transhi-
atal esophagectomy is a safe approach in appropriately
selected patients. Radical resections, postoperative com-
plication rates and survival results were in line with data
reported for traditional transthoracic approaches. Some
units restrict transhiatal esophagectomy to patients
deemed unfit for thoracotomy or to patients with very
early tumours or, conversely, locally advanced tumours
where the benefits of more radical resections may be lim-
ited. However, the authors suggest that transhiatal
esophagectomy is at least a viable alternative with certain
advantages in terms of post-operative recovery, and ever
improving oncological outcomes especially when com-
bined with chemotherapy.
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